Andrea S. Blevins Primeau

Researchers sought to determine whether eltrombopag and cyclosporin A would be effective as a first-line treatment for patients with severe aplastic anemia.

Researchers sought to characterize long-term outcomes in pediatric patients with thromboembolic pulmonary embolism.

A chimeric antigen receptor (CAR) T-cell therapy produced “dramatic and rapid” responses in 3 patients with recurrent glioblastoma, but responses were transient in 2 of the patients, according to researchers.

Researchers sought to determine pain attitudes for patients with bleeding disorders and how this was associated with pain and medication use.

Researchers sought to determine whether rusfertide would be effective in patients with polycythemia vera.

Researchers sought to determine whether brentuximab vedotin combined with dacarbazine or nivolumab would be beneficial in first-line treatment of older patients with cHL.

Azacitidine failed to elicit confirmed responses among pediatric patients with newly-diagnosed myelodysplastic syndromes (MDS), according to the results of a phase 2 study published in the journal Pediatric Blood & Cancer.

Adding palbociclib, with or without avelumab, to fulvestrant does not improve outcomes in patients with hormone receptor (HR)-positive, HER2-negative

Researchers sought to determine whether the COST tool would standardize the measurement of financial toxicity among patients with multiple myeloma.

Overall survival (OS) and other efficacy outcomes were worse among patients with multiple myeloma (MM) treated with elotuzumab-based regimens after having received daratumumab compared with patients who did not have prior daratumumab, according to a retrospective study published in the Annals of Hematology. However, this decrease in efficacy was somewhat attenuated when elotuzumab was administered 180 days or more after daratumumab or if given nonsequentially.